Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(01): 092-096
DOI: 10.4103/2278-330X.126574
Brainteaser

Chronic myeloid leukemia: When the going gets tough

Lucy A. Pickard
Department of Hematology, Kingston Hospital NHS Foundation Trust
,
Graham Knee
Department of Histopathology, Kingston Hospital NHS Foundation Trust
,
Vishal Jayakar
Department of Hematology, Kingston Hospital NHS Foundation Trust
› Author Affiliations Source of Support: Nill.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hiwase DK, Yeung DT, White DL. Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Rev Hematol 2011;4:285-99.
  • 2 Soverini S, Iacobucci I, Baccarani M, Martinelli G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007;92:437-9.
  • 3 Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88.